文献速递甲状腺与颈部外科围术期管理与 ERAS

甲状旁腺切除术及辅助治疗对骨密度临床意义改善的频率:多中心研究

How frequently does parathyroidectomy and adjuvant treatment lead to clinically meaningful changes in bone mineral density? A multi-institutional study.
PubMed 文献 · Surgery · 2026-09-01

本研究纳入490例在3家机构接受治愈性甲状旁腺切除术的成人,评估术后3年内总髋部骨密度改善≥3.18%的比例。结果显示45.2%的患者达到有临床意义的骨密度改善,双膦酸盐的附加获益和最佳时机尚不确定。

要点

  • 甲状旁腺切除术后45.2%患者总髋部骨密度改善≥3.18%。
  • 术前未用双膦酸盐者,术后不同时机启用改善率相似。
  • 双膦酸盐的附加获益和最佳时机仍不确定。

核心结论

  • 单纯甲状旁腺切除术可使45.2%的患者获得有临床意义的骨密度改善。
  • 双膦酸盐的附加获益和最佳时机尚不确定,需更好的辅助策略促进骨骼恢复。

研究设计与样本

  • 多中心回顾性研究,纳入490例在3家机构接受治愈性甲状旁腺切除术的成人。
  • 患者术前3年内及术后3年内均接受骨密度检测。

主要发现

  • 平均年龄66.9岁,平均术前血钙10.7 mg/dL。
  • 总体45.2%(95%可信区间40.8%-50%)在3年内达到有临床意义的骨密度改善。
  • 术前未用双膦酸盐者中,从未使用、术后1年内启用、术后1年后启用的改善率分别为43.3%、53.6%、48.5%。
  • 术前使用双膦酸盐者中,术后停药、1年内重启、1年后重启的改善率分别为37.9%、36.1%、46.8%。

关键数值与推荐

  • 以总髋部骨密度改善≥3.18%作为有临床意义的阈值。

临床怎么用

  • 甲状旁腺切除术后应评估骨密度以识别可能获益的患者。
  • 双膦酸盐辅助治疗的启用时机需个体化,目前证据不足以确定最佳策略。

局限性

  • 原文未报告研究设计类型(回顾性或前瞻性)的明确说明。
  • 双膦酸盐亚组分析为观察性比较,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The US Food and Drug Administration adopted percentage change in total hip bone mineral density as a validated surrogate end point to support clinical trials for osteoporosis. We evaluated the impact of parathyroidectomy for primary hyperparathyroidism on bone density using this new standard, with or without bisphosphonate therapy. METHODS: We included 490 adults who underwent curative parathyroidectomy at 3 institutions and had bone mineral density testing within 3 years before and after surgery. We calculated the proportion achieving ≥3.18% improvement in total hip bone mineral density, with subgroup analyses by bisphosphonate use before and after surgery. RESULTS: Mean age was 66.9 years, and mean preoperative calcium was 10.7 mg/dL. Overall, 45.2% (95% credible interval, 40.8%-50%) achieved meaningful bone mineral density improvement within 3 years. Among patients not on bisphosphonates preoperatively, rates were similar whether bisphosphonates were never used (43.3%), started within 1 year (53.6%), or beyond 1 year after surgery (48.5%). For patients on bisphosphonates preoperatively, improvement occurred in 37.9% if discontinued postoperatively, 36.1% if restarted within 1 year, and 46.8% if restarted after 1 year. CONCLUSION: Parathyroidectomy alone results in clinically meaningful bone mineral density improvement in 45.2% of patients. The additive benefit and optimal timing of bisphosphonates remain uncertain, underscoring the need for better adjuvant strategies, with respect to bone health, to enhance skeletal recovery after surgery.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Druar N, Finn CB, Cher BA, et al. How frequently does parathyroidectomy and adjuvant treatment lead to clinically meaningful changes in bone mineral density? A multi-institutional study. Surgery. 2026. PMID: 42778489. doi:10.1016/j.surg.2026.110589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。